Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Management of Pediatric Aggressive Mature B-Cell Lymphoma
Clinicians who treat pediatric BL and DLBCL need to be informed about the recommendations in the new NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas so that they can appropriately stratify patients into risk groups, plan initial therapy, and manage common supportive care issues. They also need information on recommended surveillance protocols and treatment of relapsed/refractory disease.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Evolution of CAR T-Cell Therapy
CAR T-cell therapy represents a novel class of immunotherapy and its use has been expanding in relapsed or refractory hematologic malignancies. To ensure optimal patient outcomes, treatment-related toxicities must be closely monitored and quickly managed.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Updates on CAR T-cell Therapy for Relapsed/Refractory B-Cell Lymphomas
There is a clear need to educate clinicians regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of adverse events and effective management strategies.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Understanding the Molecular Heterogeneity of Diffuse Large B-Cell Lymphomas and the Place of Targeted Therapies in Treatment
New promising combinations of chemoimmunotherapy with antibody drug conjugates, and small molecule inhibitors may offer an alternative approach for patients with relapsed or refractory disease. Many of these new therapies are oral and will be managed by a multidisciplinary team.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - B-Cell Lymphomas, Version 5.2021
These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of relapsed/refractory disease.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation